Lipidoids: A Combinatorial Approach to siRNA Delivery

The safe and effective delivery of siRNA remains the principal challenge to the realization of its clinical potential. The present collection of delivery materials and their diversity remains limited, in part due to their slow, multistep syntheses. This chapter will describe a class of lipid-like delivery molecules, termed “lipidoids,” as carriers for RNAi therapeutics. Specifically, the chapter will address the rationale underlying the combinatorial approach; the synthetic chemical methods employed; the screening assay utilized; the structure–activity relationships determined; the formulation considerations learned; several applications of the platform; and the evolution of the strategy to generate next-generation libraries.

[1]  D. Scherman,et al.  A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[2]  Michael S. Goldberg,et al.  Effective RNAi-mediated gene silencing without interruption of the endogenous microRNA pathway , 2007, Nature.

[3]  Phillip A Sharp,et al.  Promoting Convergence in Biomedical Science , 2011, Science.

[4]  V. Hornung,et al.  siRNA and isRNA: two edges of one sword. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.

[5]  M. G. Finn,et al.  Click Chemistry: Diverse Chemical Function from a Few Good Reactions. , 2001, Angewandte Chemie.

[6]  Michael S. Goldberg,et al.  Drug Delivery–mediated Control of RNA Immunostimulation , 2009, Molecular Therapy.

[7]  M. Manoharan,et al.  RNAi therapeutics: a potential new class of pharmaceutical drugs , 2006, Nature chemical biology.

[8]  J. Heyes,et al.  Cationic lipid saturation influences intracellular delivery of encapsulated nucleic acids. , 2005, Journal of controlled release : official journal of the Controlled Release Society.

[9]  Matthias John,et al.  RNAi-mediated gene silencing in non-human primates , 2006, Nature.

[10]  C. Bertozzi,et al.  A "traceless" Staudinger ligation for the chemoselective synthesis of amide bonds. , 2000, Organic letters.

[11]  K. Heeg,et al.  Modifications in Small Interfering RNA That Separate Immunostimulation from RNA Interference1 , 2008, The Journal of Immunology.

[12]  Michael S. Goldberg,et al.  Assessing siRNA pharmacodynamics in a luciferase-expressing mouse. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

[13]  Keith Bowman,et al.  Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs , 2005, Nature Biotechnology.

[14]  Andrew D. Miller Cationic Liposomes for Gene Therapy , 1998 .

[15]  Theresa A. Storm,et al.  Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways , 2006, Nature.

[16]  K. G. Rajeev,et al.  Rational design of cationic lipids for siRNA delivery , 2010, Nature Biotechnology.

[17]  L. Medina-Kauwe,et al.  Intracellular trafficking of nonviral vectors , 2005, Gene Therapy.

[18]  Daniel G. Anderson,et al.  Knocking down barriers: advances in siRNA delivery , 2009, Nature Reviews Drug Discovery.

[19]  Anton P. McCaffrey,et al.  Inhibition of hepatitis B virus in mice by RNA interference , 2003, Nature Biotechnology.

[20]  Michael S. Goldberg,et al.  Screening, synthesis, and applications of "lipidoids", a novel class of molecules developed for the delivery of RNAi therapeutics , 2008 .

[21]  Anton P. McCaffrey,et al.  Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMA-expressing tumors , 2009, Nature Biotechnology.

[22]  Daniel G. Anderson,et al.  Synergistic silencing: combinations of lipid-like materials for efficacious siRNA delivery. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

[23]  Daniel G Anderson,et al.  Electrostatic surface modifications to improve gene delivery , 2010, Expert opinion on drug delivery.

[24]  H. Himmelbauer,et al.  An endoribonuclease-prepared siRNA screen in human cells identifies genes essential for cell division , 2004, Nature.

[25]  Wolfgang A. Weber,et al.  Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging , 2007, Proceedings of the National Academy of Sciences.

[26]  D. Livingston,et al.  BRCA1 and BRCA2: breast/ovarian cancer susceptibility gene products and participants in DNA double-strand break repair. , 2010, Carcinogenesis.

[27]  R. Wattiaux,et al.  Endosomes, lysosomes: their implication in gene transfer. , 2000, Advanced drug delivery reviews.

[28]  R. Langer,et al.  Accelerated discovery of synthetic transfection vectors: parallel synthesis and screening of a degradable polymer library. , 2001, Journal of the American Chemical Society.

[29]  Mark E. Davis,et al.  Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles , 2010, Nature.

[30]  Robert Langer,et al.  A combinatorial library of lipid-like materials for delivery of RNAi therapeutics , 2008, Nature Biotechnology.

[31]  Matthias John,et al.  Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs , 2004, Nature.

[32]  F. Szoka,et al.  Chloride Accumulation and Swelling in Endosomes Enhances DNA Transfer by Polyamine-DNA Polyplexes* , 2003, Journal of Biological Chemistry.

[33]  Douglas S. Conklin,et al.  Gene expression: RNA interference in adult mice , 2002, Nature.

[34]  Michael S. Goldberg,et al.  Development of lipidoid-siRNA formulations for systemic delivery to the liver. , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.

[35]  R. Burger,et al.  Intraperitoneal cisplatin and paclitaxel in ovarian cancer. , 2006, The New England journal of medicine.

[36]  J. Behr,et al.  Efficient gene transfer into mammalian primary endocrine cells with lipopolyamine-coated DNA. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[37]  M. Sioud Does the understanding of immune activation by RNA predict the design of safe siRNAs? , 2008, Frontiers in bioscience : a journal and virtual library.

[38]  P. Sharp,et al.  Nanoparticle-mediated delivery of siRNA targeting Parp1 extends survival of mice bearing tumors derived from Brca1-deficient ovarian cancer cells , 2010, Proceedings of the National Academy of Sciences.

[39]  A. Fire,et al.  Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans , 1998, Nature.

[40]  M. Bally,et al.  Controlled destabilization of a liposomal drug delivery system enhances mitoxantrone antitumor activity , 1999, Nature Biotechnology.

[41]  L. Palmer,et al.  Lipid-based systems for the intracellular delivery of genetic drugs. , 1999, Molecular membrane biology.

[42]  Dan Peer,et al.  The systemic toxicity of positively charged lipid nanoparticles and the role of Toll-like receptor 4 in immune activation. , 2010, Biomaterials.

[43]  Patrick J. Paddison,et al.  A resource for large-scale RNA-interference-based screens in mammals , 2004, Nature.

[44]  M. Bally,et al.  Comparison of different hydrophobic anchors conjugated to poly(ethylene glycol): effects on the pharmacokinetics of liposomal vincristine. , 1998, Biochimica et biophysica acta.

[45]  Claes Wahlestedt,et al.  RNA Interference with chemically modified siRNA. , 2006, Current topics in medicinal chemistry.

[46]  Robert Langer,et al.  Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates , 2008, Proceedings of the National Academy of Sciences.

[47]  Michael S. Goldberg,et al.  Claudin-3 gene silencing with siRNA suppresses ovarian tumor growth and metastasis , 2009, Proceedings of the National Academy of Sciences.

[48]  Daniel G. Anderson,et al.  Combinatorial approach to determine functional group effects on lipidoid-mediated siRNA delivery. , 2010, Bioconjugate chemistry.

[49]  J. Rossi,et al.  An Aptamer-siRNA Chimera Suppresses HIV-1 Viral Loads and Protects from Helper CD4+ T Cell Decline in Humanized Mice , 2011, Science Translational Medicine.

[50]  J. Wolff,et al.  Breaking the bonds: non-viral vectors become chemically dynamic. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

[51]  Reuven Agami,et al.  A large-scale RNAi screen in human cells identifies new components of the p53 pathway , 2004, Nature.

[52]  Kathryn A. Whitehead,et al.  Lipid-like materials for low-dose, in vivo gene silencing , 2010, Proceedings of the National Academy of Sciences.

[53]  E. Wisse,et al.  The size of endothelial fenestrae in human liver sinusoids: implications for hepatocyte-directed gene transfer , 2008, Gene Therapy.

[54]  A. Lee,et al.  Design of noninflammatory synthetic siRNA mediating potent gene silencing in vivo. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.

[55]  Todd M. Allen,et al.  Inhibition of HIV transmission in human cervicovaginal explants and humanized mice using CD4 aptamer-siRNA chimeras. , 2011, The Journal of clinical investigation.

[56]  R. Langer,et al.  Lipid‐based nanotherapeutics for siRNA delivery , 2010, Journal of internal medicine.

[57]  Daniel G. Anderson,et al.  Heme oxygenase-1 is an anti-inflammatory host factor that promotes murine plasmodium liver infection. , 2008, Cell Host and Microbe.

[58]  L. Palmer,et al.  Stabilized plasmid-lipid particles: construction and characterization , 1999, Gene Therapy.